Open Access
Open access
Wiley
Cancer Medicine
,  том 14 ,  издание 3 ,  номер публикации e70369

Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study

Geoffrey Liu 1
, 
Shi Feng Nyaw 2
, 
Tony S. K. Mok 3
, 
Hubert Curcio 4
, 
Alexis B. Cortot 5
, 
Tsz Yeung Kam 6
, 
Renaud Descourt 7
, 
Yin Kwan Chik 8
, 
Parneet Cheema 9
, 
James M Gwinnutt 10
, 
Eric N. Churchill 11
, 
Justin Nyborn 12
, 
Eileen Curran 13
, 
Alexandra Savell 12
, 
Yu Yin 14
, 
Katie Chong 15
, 
Yuka Tanaka‐Chambers 16
, 
Julian Kretz 17
, 
Jacques Cadranel 18
1
 
2
 
Department of Clinical Oncology Tuen Mun Hospital Hong Kong China | 
3
 
4
 
Oncology Department Centre Francois Baclesse Caen France | 
5
 
6
 
Department of Clinical Oncology Pamela Youde Nethersole Eastern Hospital Main Block Hong Kong China | 
7
 
8
 
Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China | 
9
 
10
 
Epidemiology and Database Studies IQVIA Reading England UK | 
11
 
12
 
Global Medical Affairs Oncology, Takeda Development Center Americas, Inc. Lexington Massachusetts USA | 
13
 
Global Evidence and Outcome Research Takeda Development Center Americas, Inc. Lexington Massachusetts USA | 
14
 
Observational Research Analytics Takeda Development Center Americas, Inc. Lexington Massachusetts USA | 
15
 
Clinical Data Management Takeda Development Center Americas, Inc. Lexington Massachusetts USA | 
16
 
Statistical and Quantitative Sciences Takeda Development Center Americas, Inc. Lexington Massachusetts USA | 
17
 
18
 
Тип публикации: Journal Article
Дата публикации: 2025-01-24
Wiley
scimago Q1
wos Q2
БС2
SJR: 1.201
CiteScore: 5.0
Impact factor: 3.1
ISSN: 20457634
Краткое описание
ABSTRACT
Background

Real‐world data regarding patients with non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.

Methods

A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423). The inclusion criteria were: ≥ 18 years old; diagnosis of stage IIIB‐IV NSCLC with EGFR ex20ins between January 1, 2017 and November 30, 2021; received mobocertinib. Data on demographics, clinical parameters, treatment patterns, mobocertinib exposure, real‐world outcomes, and adverse events (AEs) were collected. Results are also reported by Asian/Non‐Asian races.

Results

Overall, 105 patients were enrolled (median [IQR] age at initial diagnosis: 64.0 years [56, 71]; women: 62.9%). The most common first‐line of therapy (LoT) was chemotherapy; the most common second LoT was EGFR tyrosine kinase inhibitors. Most patients received mobocertinib during LoT two and three (74.3%); the maximum dose was 160 mg/day for 67.6% of the cohort (mean [SD] daily dose: 130.6 mg [36.68]). The median real‐world progression‐free survival (PFS) on mobocertinib was 4.76 months (95% CI: 3.98, 6.21). The overall response rate and disease control rate were 20.0% and 48.6%, respectively (median duration of response: 8.34 months [95% CI: 3.61, 9.49]). The median overall survival (OS) was 26.28 months (95% CI: 20.21, 36.44). Asian patients had numerically superior PFS and OS compared with non‐Asian patients. Regarding safety analysis, 73 patients (69.5%) experienced any AE. The most common AE was diarrhea (any grade) (52 patients; 49.5%).

Conclusions

These data illustrate the real‐world effectiveness of mobocertinib.

Найдено 
Найдено 

Топ-30

Журналы

1
Current Oncology
Current Oncology, 1, 100%
Current Oncology
1 публикация, 100%
1

Издатели

1
MDPI
MDPI, 1, 100%
MDPI
1 публикация, 100%
1
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
1
Поделиться
Цитировать
ГОСТ |
Цитировать
ГОСТ Скопировать
Liu G. et al. Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study // Cancer Medicine. 2025. Vol. 14. No. 3. e70369
ГОСТ со всеми авторами (до 50) Скопировать
Liu G., Nyaw S. F., Mok T. S. K., Curcio H., Cortot A. B., Kam T. Y., Descourt R., Chik Y. K., Cheema P., Gwinnutt J. M., Churchill E. N., Nyborn J., Curran E., Savell A., Yin Yu., Chong K., Tanaka‐Chambers Y., Kretz J., Cadranel J. Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study // Cancer Medicine. 2025. Vol. 14. No. 3. e70369
RIS |
Цитировать
RIS Скопировать
TY - JOUR
DO - 10.1002/cam4.70369
UR - https://onlinelibrary.wiley.com/doi/10.1002/cam4.70369
TI - Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
T2 - Cancer Medicine
AU - Liu, Geoffrey
AU - Nyaw, Shi Feng
AU - Mok, Tony S. K.
AU - Curcio, Hubert
AU - Cortot, Alexis B.
AU - Kam, Tsz Yeung
AU - Descourt, Renaud
AU - Chik, Yin Kwan
AU - Cheema, Parneet
AU - Gwinnutt, James M
AU - Churchill, Eric N.
AU - Nyborn, Justin
AU - Curran, Eileen
AU - Savell, Alexandra
AU - Yin, Yu
AU - Chong, Katie
AU - Tanaka‐Chambers, Yuka
AU - Kretz, Julian
AU - Cadranel, Jacques
PY - 2025
DA - 2025/01/24
PB - Wiley
IS - 3
VL - 14
SN - 2045-7634
ER -
BibTex
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2025_Liu,
author = {Geoffrey Liu and Shi Feng Nyaw and Tony S. K. Mok and Hubert Curcio and Alexis B. Cortot and Tsz Yeung Kam and Renaud Descourt and Yin Kwan Chik and Parneet Cheema and James M Gwinnutt and Eric N. Churchill and Justin Nyborn and Eileen Curran and Alexandra Savell and Yu Yin and Katie Chong and Yuka Tanaka‐Chambers and Julian Kretz and Jacques Cadranel},
title = {Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
publisher = {Wiley},
month = {jan},
url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.70369},
number = {3},
pages = {e70369},
doi = {10.1002/cam4.70369}
}